Skip to main content

REVIEW article

Front. Med.
Sec. Infectious Diseases: Pathogenesis and Therapy
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1455715
This article is part of the Research Topic Newer Initiatives in Detection, Drug Discovery and Therapeutic Management of Drug-Resistant Tuberculosis View all 5 articles

The Progress of Mycobacterium tuberculosis Drug Targets

Provisionally accepted
Xin Zhang Xin Zhang 1Ruixia Zhao Ruixia Zhao 1Yao Qi Yao Qi 1Xiong Yan Xiong Yan 1Gaoxiu Qi Gaoxiu Qi 1Qiuju Peng Qiuju Peng 2*
  • 1 Qingdao Central Hospital, Qingdao, Shandong Province, China
  • 2 Qingdao Chest Hospital, Qingdao, China

The final, formatted version of the article will be published soon.

    Tuberculosis (TB) has been troubling humans for hundreds of years, is a highly infectious disease caused by Mycobacterium tuberculosis (Mtb) infection, Mtb can infect almost all organs of the body and is one of the deadly infectious diseases in the world. At present, the first-line treatment regimen has a long treatment cycle and is prone to multiple drug resistance. Anti-tuberculosis drugs and latent tuberculosis infection (LTBI) resistance are increasing year by year, and new targets and new bioactive compounds are urgently needed to treat this disease. This review focuses on the latest reported anti-TB drug targets and related compounds in recent years, reviews the current TB drug regimen and major defects, outlines the key drug targets developed to date in Mtb, and the current situation of newly discovered anti-TB resistant forms of drugs. To provide a reference for the research and development of new anti-TB drugs and bring new treatment strategies for TB patients.

    Keywords: Mycobacterium tuberculosis, Anti-tuberculosis drug, target, Cell wall synthesis correlation, DNA / RNA synthesis correlation, Energy Metabolism

    Received: 27 Jun 2024; Accepted: 02 Oct 2024.

    Copyright: © 2024 Zhang, Zhao, Qi, Yan, Qi and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Qiuju Peng, Qingdao Chest Hospital, Qingdao, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.